QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
NASDAQ:UTRS

Minerva Surgical - UTRS Stock Forecast, Price & News

$0.38
+0.01 (+2.69%)
(As of 01/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.35
$0.40
50-Day Range
$0.16
$0.43
52-Week Range
$0.15
$6.04
Volume
1.34 million shs
Average Volume
2.99 million shs
Market Capitalization
$11.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Minerva Surgical MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1,211.0% Upside
$5.00 Price Target
Short Interest
Healthy
4.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.43mentions of Minerva Surgical in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.20) to ($1.15) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.48 out of 5 stars

Medical Sector

178th out of 1,055 stocks

Surgical & Medical Instruments Industry

19th out of 106 stocks


UTRS stock logo

About Minerva Surgical (NASDAQ:UTRS) Stock

Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.

Receive UTRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Minerva Surgical and its competitors with MarketBeat's FREE daily newsletter.

UTRS Stock News Headlines

UTRS Minerva Surgical, Inc.
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Minerva Surgical Appoints Todd Usen As CEO To Succeed David Clapper
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Minerva Surgical Announces Time To Talk Campaign
See More Headlines
Receive UTRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Minerva Surgical and its competitors with MarketBeat's FREE daily newsletter.

UTRS Company Calendar

Last Earnings
11/14/2022
Today
1/31/2023
Next Earnings (Estimated)
3/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:UTRS
Fax
N/A
Employees
157
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+1,211.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-21,460,000.00
Pretax Margin
-34.01%

Debt

Sales & Book Value

Annual Sales
$52.10 million
Book Value
$1.53 per share

Miscellaneous

Free Float
27,282,000
Market Cap
$11.37 million
Optionable
Not Optionable
Beta
-0.16

Key Executives

  • Mr. David M. ClapperMr. David M. Clapper (Age 71)
    Consultant
    Comp: $848.92k
  • Mr. Joel R. Jung MBA (Age 65)
    Chief Financial Officer
    Comp: $461.6k
  • Mr. Dominique J. Filloux (Age 60)
    Chief Operating Officer
    Comp: $471.6k
  • Mr. Thomas Pendlebury
    VP of Sales & Marketing
  • Ms. Wendy Bowman
    VP of HR
  • Ms. Joanne Long
    VP of Corp. Controller
  • Dr. Evgueni V. Skalnyi M.D. (Age 57)
    VP of Medical Affairs













UTRS Stock - Frequently Asked Questions

Should I buy or sell Minerva Surgical stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Minerva Surgical in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" UTRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in UTRS, but not buy additional shares or sell existing shares.
View UTRS analyst ratings
or view top-rated stocks.

What is Minerva Surgical's stock price forecast for 2023?

2 brokers have issued 1 year price objectives for Minerva Surgical's shares. Their UTRS share price forecasts range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 1,211.0% from the stock's current price.
View analysts price targets for UTRS
or view top-rated stocks among Wall Street analysts.

How have UTRS shares performed in 2023?

Minerva Surgical's stock was trading at $0.2234 at the beginning of the year. Since then, UTRS shares have increased by 70.7% and is now trading at $0.3814.
View the best growth stocks for 2023 here
.

Are investors shorting Minerva Surgical?

Minerva Surgical saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 448,500 shares, a decline of 51.2% from the December 31st total of 918,400 shares. Based on an average daily volume of 1,020,000 shares, the days-to-cover ratio is currently 0.4 days. Approximately 4.4% of the shares of the company are short sold.
View Minerva Surgical's Short Interest
.

When is Minerva Surgical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our UTRS earnings forecast
.

How were Minerva Surgical's earnings last quarter?

Minerva Surgical, Inc. (NASDAQ:UTRS) issued its quarterly earnings results on Monday, November, 14th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.12. The business had revenue of $12.59 million for the quarter, compared to analyst estimates of $12.64 million. Minerva Surgical had a negative net margin of 34.03% and a negative trailing twelve-month return on equity of 51.99%.

What guidance has Minerva Surgical issued on next quarter's earnings?

Minerva Surgical updated its FY 2022 earnings guidance on Wednesday, December, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $50.00 million-$53.00 million, compared to the consensus revenue estimate of $50.85 million.

When did Minerva Surgical IPO?

(UTRS) raised $100 million in an IPO on Friday, October 22nd 2021. The company issued 6,250,000 shares at $15.00-$17.00 per share.

What is Minerva Surgical's stock symbol?

Minerva Surgical trades on the NASDAQ under the ticker symbol "UTRS."

How do I buy shares of Minerva Surgical?

Shares of UTRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Minerva Surgical's stock price today?

One share of UTRS stock can currently be purchased for approximately $0.38.

How much money does Minerva Surgical make?

Minerva Surgical (NASDAQ:UTRS) has a market capitalization of $11.37 million and generates $52.10 million in revenue each year.

How many employees does Minerva Surgical have?

The company employs 157 workers across the globe.

How can I contact Minerva Surgical?

The official website for the company is www.minervasurgical.com. The company can be reached via phone at 855-646-7874 or via email at caroline.corner@westwicke.com.

This page (NASDAQ:UTRS) was last updated on 1/31/2023 by MarketBeat.com Staff